Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Personnel Change of ASKA Pharmaceutical
ASKA Obtains Manufacturing and Marketing Approval for OralContraceptive Slinda 28 Tablets in Japan
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch
[Updated]Notice Concerning the Opinion of the Board of Directors of the Company on the Shareholder Proposal
[Updated]Financial Results for FY2024
ASKA Pharma, 33% Increase in Ordinary Profit, Record High for The First Time in Two Years, Increased Previous Year's Dividend by 5 yen, Plan to Continue the 55 yen Policy This Fiscal Year as Well
[Summary]Consolidated Financial Results for FY2024
Notice Concerning Dividends of Surplus
Notice Concerning the Opinion of the Board of Directors of the Company on the Shareholder Proposal